Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions

Allschwil, Switzerland – November 11, 2024 Idorsia Ltd today announced that new data on aprocitentan, the first-and-only dual endothelin receptor antagonist for the treatment of systemic hypertension, will be presented at the American Heart Association annual Scientific Sessions 2024, taking place in Chicago, Illinois, November 16–18,